AI predicts when blood cancer drugs fail
NCT ID NCT05853458
Summary
This study aimed to confirm if a computer model could accurately predict when a standard drug (hydroxyurea) would stop working for patients with polycythemia vera, a type of blood cancer. It observed 76 adult patients in Germany who were starting the drug for the first time. The goal was to help doctors identify patients likely to become resistant to the treatment earlier, so they could consider switching to other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Heidelberg, Baden-Wurttemberg, 69115, Germany
-
Novartis Investigative Site
Kronach, Bavaria, 96317, Germany
-
Novartis Investigative Site
Straubing, Bavaria, 94315, Germany
-
Novartis Investigative Site
Langen, Hesse, 63225, Germany
-
Novartis Investigative Site
Lingen Ems, Lower Saxony, 49808, Germany
-
Novartis Investigative Site
Aachen, North Rhine-Westphalia, 52064, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50674, Germany
-
Novartis Investigative Site
Dortmund, North Rhine-Westphalia, 44309, Germany
-
Novartis Investigative Site
Velbert, North Rhine-Westphalia, 42551, Germany
-
Novartis Investigative Site
Saarbrücken, Saarland, 66113, Germany
-
Novartis Investigative Site
Merseburg, Saxony-Anhalt, 06217, Germany
-
Novartis Investigative Site
Lübeck, Schleswig-Holstein, 23563, Germany
-
Novartis Investigative Site
Berlin, 10407, Germany
-
Novartis Investigative Site
Donauwörth, 86609, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Erding, 85435, Germany
-
Novartis Investigative Site
Gütersloh, 33332, Germany
-
Novartis Investigative Site
Hanover, 30161, Germany
-
Novartis Investigative Site
Kiel, 24105, Germany
-
Novartis Investigative Site
Mutlangen, 73557, Germany
-
Novartis Investigative Site
Naunhof, 04683, Germany
-
Novartis Investigative Site
Westerstede, 26655, Germany
-
Novartis Investigative Site
Würselen, 52146, Germany
Conditions
Explore the condition pages connected to this study.